Leukotriene (LT) C4 synthase catalyzes the conjugation of LTA4 with reduced glutathione (GSH) to form LTC4, the parent compound of cysteinyl leukotrienes. It is a 18 kDa protein that functions as homodimer. Cloning of LTC4 synthase cDNA reveals amino acid homology with 5-lipoxygenase activating protein (FLAP) and newly identified microsomal glutathione S-transferase II (mGST-II) but not with cytosolic GSTs or mGST-I. LTC4 synthase gene contains 5 exons and four introns. This gene has been localized to the long arm of human chromosome 5 at the region of 5q35 which is in close proximity to the cluster of genes that are involved in inflammation and asthma. Mutagenic studies reveals that amino acid residues Arg-51 and Tyr-93 are critical for catalytic function. Arg-51 was proposed to open the epoxide ring of LTA4 and Tyr-93 to provide the thiolate anion of GSH.
ABSTRACT
Leukotriene (LT) C4 synthase catalyzes the conjugation of LTA4 with reduced glutathione (GSH) to form LTC4, the parent compound of cysteinyl leukotrienes. It is a 18 kDa protein that functions as homodimer. Cloning of LTC4 synthase cDNA reveals amino acid homology with 5-lipoxygenase activating protein (FLAP) and newly identified microsomal glutathione S-transferase II (mGST-II) but not with cytosolic GSTs or mGST-I. LTC4 synthase gene contains 5 exons and four introns. This gene has been localized to the long arm of human chromosome 5 at the region of 5q35 which is in close proximity to the cluster of genes that are involved in inflammation and asthma. Mutagenic studies reveals that amino acid residues Arg-51 and Tyr-93 are critical for catalytic function. Arg-51 was proposed to open the epoxide ring of LTA4 and Tyr-93 to provide the thiolate anion of GSH.
INTRODUCTION
Asthma is characterized by episodic bronchoconstriction, hyper-responsiveness, and inflammation of the conducting airways (1, 2) . The inflammatory responses in asthma include luminal plugging with mucus, epithelial cells, and eosinophils (3, 4) ; denudation of the epithelium (5) with subepithelial collagen deposition (6) ; and infiltration of the epithelium and submucosa with eosinophils and TH-2 cells (7-9). In addition, there are partial degranulation of mast cells and eosinophils (7) and release of both the preformed granule enzymes and the newly-generated lipid mediators such as The specific involvement of leukotrienes in asthma is suggested by their potent biological activities, their presence in the airways in asthma, and the effect of 5-lipoxygenase (5-LO) inhibitors and LTD4 receptor antagonist in asthma. Inhaled LTC4 or LTD4 are 1,000-fold, and LTE4 10-fold, more potent than histamine in compromising airway function in normal subjects. LTC4, LTD4 and LTE4 displayed similar potency and are more active in reducing lung functions in patients with asthma (10). They stimulate mucus secretion from bronchial epithelial cells and increase pulmonary vascular permeability via endothelial cell contraction at the post capillary venules (11) (12) (13) . The cysteinyl leukotrienes have been recovered from the airways of asthmatic individuals both at rest (14) and following allergen challenge (15) or isocapnic hyperventilation (16) . Clinical studies with 5-LO inhibitors and 5-lipoxygenase activating protein (FLAP) inhibitors, agents that inhibit leukotrienes formation, and with leukotriene antagonists, has permitted a definitive examination of the role of leukotrienes in bronchial asthma. Administration of these agents, which devoid of intrinsic bronchodilatory activity, leads to bronchodilatation in patients with asthma (17, 18) , suggesting that leukotrienes contribute to the abnormal resting airway tone in asthma. These compound inhibit acute asthmatic response to exercise (19, 20) , cold-dry air (21), allergen (22) and aspirin (23, 24) . They decrease the late asthmatic response to allergen and the accompanying airway hyper-responsiveness (22) , and reduced the severity of chronic asthma (25) , all of which support the role of cysteinyl leukotrienes contributing to the pathogenesis of bronchial asthma. The formation of cysteinyl leukotrienes in mast cells and eosinophils is initiated upon agonist stimulation and increase in intracellular Ca ++ and activation of cytosolic PLA2. PLA2 hydrolyze and release arachidonic acid (AA) from membrane phospholipids (26) . The released AA binds to 5-lipoxygenase activating protein (FLAP) and is presented to 5-lipoxygenase (27) . 5-lipoxygenase converts AA to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently to LTA4 (28) . LTC4 synthase, an integral membrane protein, conjugates LTA4 with reduced glutathione (GSH) to form the LTC4 (29, 30) , the parent compound of cysteinyl leukotrienes. Following carrier-mediated export (31), sequential cleavage of glutamic acid and glycine from the glutathione moiety of LTC4 yields the receptor active derivatives, LTD4 and LTE4 (32, 33) , respectively.
BIOCHEMICAL PROPERTIES OF NATIVE LTC4 SYNTHASE
Although LTC4 synthase conjugates glutathione, it was recognized to differ other glutathione S-transferase (GST), by its selectivity for LTA4 and its analogs, and failure to conjugate xenobiotics (34) . The enzyme is expressed in a limited number of cell types such as eosinophils (35) , mast cells (36) and monocyte/macrophages (37) and in leukemic cell lines such as KG-1 cells (38) and THP-1 cells (39); it is also present in platelets (40) which lack 5-lipoxygenase.
Certain cytosolic and microsomal GSTs can conjugate GSH to either a xenobiotic or LTA4 (41, 42) , but their role in the inflammatory response is not evident at present. LTC4 synthase from guinea pig lung, KG-1, THP-1 and U-937 cells as well as from human platelets (29, (38) (39) (43) (44) has been distinguished from cytosolic and microsomal GSTs not only by a narrow substrate specificity, but also by differential susceptibility to inhibitors and immunoreactivity. Partially purified LTC4 synthase isolated from guinea lung has been demonstrated to conjugates only LTA4 and its structural isomers with GSH and does not utilize xenobiotics as substrates (Table  1) (29, 30) . LTC4 synthase purified from the DMSO- LTC4 synthase isolated from THP-1 cells and from DMSO-differentiated U-937 cells does not cross react with antibodies to human microsomal GST or to human alpha, Mu and Pi class of cytosolic GSTs (39, 43) . In contrast, rabbit polyclonal antiserum raised against purified human lung LTC4 synthase recognized the 18 kDa LTC4 synthase purified from KG-1 cells, human lung, and COS cells transfected with LTC4 synthase cDNA in western blot analysis (45) . In addition, this antibody also recognized an 18 kDa protein from human platelets, in vitro derived human eosinophils and mouse bone marrowderived mast cells (45, 46) . Immunohistochemical analysis of sections of human lung disclosed that the subcellular localization of human LTC4 synthase in alveolar macrophages is perinuclear in distribution (45) .
Recently, LTC4 synthase was purified to homogeneity as an 18 kDa protein from human leukemic KG-1 cells using probenecid as a novel elution reagent for S-hexyl glutathione chromatography followed by gel electrophoresis (38) . Purification of an 18 kDa protein was also achieved from THP-1 cells (39). The 18 kDa protein was proposed to function as a homodimer based on the size of the active fraction by gel filtration column chromatography (39,47).
LTC4 SYNTHASE cDNA
A novel fluorescence-linked competitive immunoassay, sensitive to 2.5 pg of LTC4, was developed for expression cloning of human LTC4 synthase (48) . Using this method for first round of screening of 2. The nucleotide sequence of the cDNA and the deduced amino acid sequence of human LTC4 synthase do not share significant homology with the xenobiotic active GSTs. However, protein sequence analysis revealed 31% overall amino acid identity with FLAP. The amino acid identity at the N-terminal 2/3 of these proteins is 44% which includes the putative FLAP inhibitor binding domain ( Fig. 1)(49) . The predicted secondary structure of the deduced LTC4 synthase is nearly identical to that of FLAP with their 3 hydrophobic domains overlap each other and 2 identical sized hydrophilic loops.
These features of human LTC4 synthase was conserved in mouse LTC4 synthase (50) . Mouse LTC4 synthase is also an 150 amino acid residue polypeptide. It differs from human LTC4 synthase in 18 amino acid residues, 9 of which are located at the carboxy-terminus of the protein.
The putative FLAP inhibitor binding domain (with 2 conservative substitution of Y50F and T41S), the potential N-glycosylation site and the two potential PKC phosphorylation sites are present in mouse LTC4 synthase.
Recently, a new microsomal glutathione Stransferase (mGST-II) has been identified that displayed 44% overall amino acid identity with human LTC4 synthase (42) which also includes the putative FLAP inhibitor binding domain-like region. The predicted secondary structure of mGST-II is similar to that of LTC4 synthase and FLAP suggesting that these three proteins belongs to a new gene family.
BIOCHEMICAL PROPERTIES OF RECOMBINANT LTC4 SYNTHASE
Kinetic analysis of S-hexyl-GSH agarose affinity purified recombinant human and mouse LTC4 synthase showed near identical Km and Vmax values ( Table 2) . These Km and Vmax values are also in close agreement with the published value for LTA4 free acid and GSH using enzyme purified from human leukemic cells (43). The amino acid residue substitutions in the putative FLAP inhibitor binding domain-like region of mouse LTC4 synthase did not modify the effect of a FLAP inhibitor, MK-886. The IC50 for human and mouse recombinant LTC4 synthase were 3.1 µM and 2.7 µM, respectively. These results indicate that the amino acid substitutions observed in mouse LTC4 synthase do not affect enzyme function and further suggest that the carboxyl terminal end of LTC4 synthase are not important in either the binding or the catalytic function of the enzyme.
CATALYTIC MECHANISM OF CONJUGATION
Site-directed mutagenesis was carried out to determine the substrate binding site and the catalytic mechanism of human LTC4 synthase (47) . Mutation of the Arg-51 of the first hydrophilic loop to Thr or Ile abolishes function of the recombinant protein, whereas mutations of Arg-51 to His or Lys provide a fully active recombinant protein. Mutation of V49F, A52S, N55A and Y59F of the first hydrophilic loop, and mutations of Y97F and Y93F of the second hydrophilic loop, increases the Km of the recombinant enzyme for GSH suggested that these residues are involved in GSH binding. The mutation of Y93F also markedly reduces function and shifts the optimum for pH dependent activity. Direct linkage of two LTC4 synthase monomers by a 12 amino acid bridge provides an active covalent-linked dimer and identical bridging of inactive R51I with a wild type monomer also creates an active pseudo-heterodimer. These results suggest that Arg-51 and Tyr-93 are involved in catalysis with Arg-51 opening the epoxide ring and Tyr-93 providing the thiolate anion of glutathione. That a wild type monomer linked to an inactive monomer has full function suggests that each monomer of LTC4 synthase has independent conjugation activity and that dimerization of LTC4 synthase maintains the proper protein folding. It is interesting to point out that the amino acid residue Tyr-93 is present in both mGST-II and FLAP. In contrast, Arg-51 is present in mGST-II, which has the ability to conjugate Lam et al, 1996 (50) both LTA4 and xenobiotics with GSH, but is not present in FLAP which has no known GSH conjugating activity.
GENOMIC ORGANIZATION OF HUMAN LTC4 SYNTHASE GENE
Human LTC4 synthase gene consists of 5 exons and 4 introns that span 2.51 kbp. (51) . The exons (ranging from 71 to 257 nucleotides) of LTC4 synthase gene are identical in size to those of FLAP with the exception of the first and fifth, which are affected minimally by the number of nucleotides in the 5' and 3' untranslated regions. Furthermore, these exons of LTC4 synthase and FLAP align identically with regard to the predicted secondary structures and the amino acids that they encode (48) . In contrast to the exons, the introns of LTC4 synthase are only 1/10th that of FLAP.
5' extension analysis of KG-1 mRNA revealed three putative transcription initiation sites in the human LTC4 synthase gene, located 66, 69, and 96 nucleotides upstream of the ATG translation start site. Similar analysis using total RNA reveals single transcription start site in THP-1 cells (52). The 1.4 kbp of the 5' flanking region of human LTC4 synthase gene contains SP-1, AP-1 and AP-2 consensus binding sequences (Figure 2) . The presence of AP-1 and AP-2 regulatory elements are consistent with the induction of LTC4 synthase activity by PMA (53) . The FLAP gene, however, has a single transcription start site and a modified TATA box (54).
CHROMOSOMAL LOCALIZATION OF HUMAN LTC4 SYNTHASE GENE
Fluorescent in-situ hybridization localized LTC4 synthase gene to the long arm of chromosome 5 at an area that corresponds to band 5q35 (51) . Human FLAP gene, however, was localized to 13q12. The region proximal of 5q35 has recently been identified as the site at which many of the genes encoding growth factors, cytokines, and receptors relevant to the asthmatic phenotype are localized, these include IL-3, IL-4, IL-5 and GM-CSF (55) . The inflammatory response in bronchial asthma is focussed on the activation of TH2 cells, eosinophils, and mast cells. IL-4 is essential to the dominance of the TH2 phenotype and to the cell switch required for IgE biosynthesis. IL-4 and IL-5 are involved in eosinophil infiltration, and IL-3, IL-5 and GM-CSF enhance the survival and function of eosinophils, including generation of LTC4. Furthermore, the disproportionate expression of certain genes within these regions of human chromosome 5 have been shown by genetic linkage studies to be highly correlated with atopic asthma.
PERSPECTIVE
Major advances have been made in the past 10 years since the initial description of SRS-A about 5 decades ago. The progressive purification and functional characterization of SRS-A led to elucidation of its composition, as cysteinyl leukotrienes.
The stereochemistry of LTC4 and its metabolites, LTD4 and LTE4, were subsequently defined by organic synthesis and by the demonstration that these synthetic compounds were equipotent to biologically derived materials in bioassays. The proteins involved in the biosynthesis of LTC4, i.e. 5-LO, FLAP and LTC4 synthase were defined and cloned. cDNA sequences and genomic organizations of these proteins revealed that two of these proteins, LTC4 synthase and FLAP, defined a new gene family. The amino acid residues responsible for the function of each of the three proteins have recently been defined and attention is now being directed to regulation of the genes and/or their polymorphism and their implications for airway diseases. Most importantly, the cysteinyl leukotrienes contained in SRS-A have proven to be exquisitely potent in impairing airflow of human airway through its contractile activity on bronchial and vascular smooth muscle. Agents that inhibit the biosynthesis cysteinyl leukotrienes or block the receptor-mediated action are, therefore, therapeutically effective in treating patients with bronchial asthma.
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